Form 4: STAAR Surgical Director's RSU Vesting

STAAR Surgical Director Wei Jiang reported the vesting of 20,967 restricted stock units, converting to common stock, as part of his compensation for strategic advisory services.

Summary

• Wei Jiang, a Director at STAAR Surgical Co. (STAA), reported a transaction involving the vesting of Restricted Stock Units (RSUs).
• On January 12, 2026, 20,967 RSUs vested, converting into 20,967 shares of STAAR Surgical common stock.
• The transaction price for the acquired common stock was $0, which is typical for RSU vesting.
• Following this transaction, Mr. Jiang directly beneficially owns 66,444 shares of common stock.
• These RSUs were originally granted on May 12, 2025, and vested in three equal tranches: August 12, 2025 (20,967 shares), November 12, 2025 (20,967 shares), and January 12, 2026 (20,967 shares).
• The vesting is related to Mr. Jiang's service as a special strategic advisor to the Corporation's Asia Pacific business, in the temporary role of Chief of APAC Strategy, through the end of fiscal 2025, as previously disclosed in a Form 8-K filed on April 24, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of equity compensation vesting, which is a positive for the director and aligns their interests with shareholders. No negative information is present.

Positives

• Vesting of RSUs indicates the fulfillment of service conditions by the director.
• Increased direct ownership of common stock by a director, aligning their interests with shareholders.

Future Outlook

The filing primarily reports a past equity transaction and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction beyond the completion of Mr. Jiang's advisory role by the end of fiscal 2025.

Management Comments

• Reflects restricted stock units (RSUs) granted to the Reporting Person on May 12, 2025.
• These RSUs vested as to 1/3 of the shares subject to the award (20,967 shares) on August 12, 2025, 1/3 (20,967 shares) on November 12, 2025, and 1/3 (20,967 shares) on January 12, 2026.
• Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.
• As disclosed in the Corporation's Current Report on Form 8-K filed on April 24, 2025, the Corporation entered into a consulting agreement with Mr. Jiang to serve as a special strategic advisor to the Corporation's Asia Pacific business through the end of fiscal 2025, in the temporary role of Chief of APAC Strategy.
• This Form 4 reflects the vesting of RSUs granted to Mr. Jiang in connection with such service.

Industry Context

This Form 4 is a routine insider transaction disclosure and does not provide specific industry context. However, the mention of a 'Chief of APAC Strategy' role for Mr. Jiang suggests STAAR Surgical's continued focus on its Asia Pacific business, a common growth area for medical device companies.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) detailing the vesting of equity compensation.
• It does not contain financial results or operational data that would allow for a direct comparison to industry-specific benchmarks or competitor performance.
• The compensation structure involving RSUs is a common practice for executive and director compensation across various industries.

Related Party Transactions

• The vesting of restricted stock units to Director Wei Jiang represents a standard form of equity compensation, which is a related party transaction between the company and its director.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders through direct equity ownership.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this routine insider transaction report.

Next Steps

• Mr. Jiang's role as special strategic advisor to the Asia Pacific business is through the end of fiscal 2025.

Key Dates

Recommendation

This Form 4 reports a routine vesting of restricted stock units for a director, Wei Jiang, which converts derivative securities into common stock. This is a standard compensation event and does not provide new information that would significantly alter the investment thesis for STAAR Surgical. The transaction aligns the director's interests with shareholders through increased equity ownership. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

STAAR Surgical, STAA, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Compensation, Equity Ownership, Wei Jiang